US Patent 11548927 Formulation of modified interleukin-7 fusion protein
Patent 11548927 was granted and assigned to Genexine on January, 2023 by the United States Patent and Trademark Office.
All edits
Edits on 29 Apr, 2023
Golden AI
Infobox
Patent Citations
Edits on 28 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
115489270
Date of Patent
January 10, 2023
0Patent Application Number
157732730
Date Filed
November 2, 2016
0Patent Citations
Patent Primary Examiner
CPC Code
Edits on 11 Jan, 2023
Golden AI
Edits made to:
Infobox (+12 properties)
Article (+578 characters)
US Patent 11548927 Formulation of modified interleukin-7 fusion protein
Article
Provided is a pharmaceutical formulation comprising a modified IL-7 protein. More particularly, it comprises (a) a modified IL-7 fusion protein; (b) a basal buffer with a concentration of 10 to 50 mM; (c) a sugar with a concentration of 2.5 to 5 w/v %; and (d) a surfactant with a concentration of 0.05 to 6 w/v %. Such pharmaceutical formulation of a modified IL-7 fusion protein does not show aggregates formation, but shows protective effects on proteins under stress conditions such as oxidation or agitation, and thus can effectively be used for the treatment of a patient.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
115489270
Date of Patent
January 10, 2023
0Patent Application Number
157732730
Date Filed
November 2, 2016
0Patent Citations
Patent Primary Examiner
CPC Code
Find more entities like US Patent 11548927 Formulation of modified interleukin-7 fusion protein
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.